University of Michigan Rogel Cancer Center
Michigan's Rogel Cancer Center is home to the TMPRSS2-ERG discovery, MI-ONCOSEQ, and pioneering degrader chemistry (Wang).
Chinnaiyan's prostate genomics, Shaomeng Wang's MDM2 and BET degraders, and precision oncology sequencing programmes.
- Prostate genomics
- Degrader chemistry
- Precision oncology
Discovered the TMPRSS2-ERG fusion in prostate cancer and built one of the first clinical sequencing programmes.
Costas Lyssiotis shows how pancreatic tumours feed off their surrounding cells and how to cut the supply.
Co-author of the Fearon-Vogelstein model of how colorectal cancer develops step by step.
Lori Pierce is a breast radiation oncologist and ASCO past president focused on equity in cancer care.
Max Wicha identified breast cancer stem cells and made them a therapeutic target.
Shaomeng Wang is the medicinal chemist behind some of the first clinical MDM2 inhibitors and PROTAC degraders.
Radiation oncologist who developed adaptive liver radiotherapy and radiosensitising drug combinations.
Immunologist who showed PD-L1 on tumours suppresses T cells and linked interferon to ferroptosis.
Pages like this
not linked directly; found by shared links- IdeaDestroy the truncated androgen receptor that hormone drugs cannot touch
Shares PROTACs & molecular glues (targeted protein degradation), Prostate cancer.
- CompanyMonte Rosa Therapeutics
Shares PROTACs & molecular glues (targeted protein degradation), Prostate cancer.
- TargetAndrogen receptor
Shares Shaomeng Wang, PROTACs & molecular glues (targeted protein degradation), Prostate cancer.
- InstitutionNRG Oncology
Shares Lori J. Pierce, Prostate cancer.